Results 31 to 40 of about 28,326 (256)

Quantification of ctDNA.

, 2023
Raw and final data with calculations of ctDNA levels before, during, and after NRT with regard to changes in tumor masses. (XLSX)
Philipp Rovedo (17319607), Matthias Jung (2866535), Konrad Kurowski (17319604), Zacharias Brugger (17319598), Hannah Fuellgraf (3584372), Anca-Ligia Grosu (126295), Balazs Bogner (17319589), Thomas Pauli (3332370), Anja Eisenhardt (17319601), Fabian Bamberg (394751), Steffen Ulrich Eisenhardt (11253360), Ute Lausch (17319592), Jurij Kiefer (766637), Alexander Runkel (17319586), Melanie Boerries (381256), Jutta Scholber (3765967), Peter Bronsert (3410321), David Braig (3765958), Anika Boneberg (17319595), Adrian Schmid (239952)   +19 more
core   +1 more source

Circulating Tumor Cells and ctDNA in Sarcomas

, 2022
Sarcomas are clustered in two oncological entities named bone and soft-tissue sarcomas. Both are rare cancers originating from the mesenchyme, characterized by their propensity to induce the development of lung metastases. Sarcoma cells escaping from the primary tumor site, spread to the pulmonary tissue through the bloodstream where they found a ...
Heymann, Dominique, Jubelin, Camille, Cochonneau, Denis, Moranton, Emilie, Muñoz-Garcia, Javier   +4 more
openaire   +2 more sources

Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology

eLife, 2021
We developed genetic-epigenetic tissue mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues.
Wanxia Gai, Ze Zhou, Sean Agbor-Enoh, Xiaodan Fan, Sheng Lian, Peiyong Jiang, Suk Hang Cheng, John Wong, Stephen L Chan, Moon Kyoo Jang, Yanqin Yang, Raymond HS Liang, Wai Kong Chan, Edmond SK Ma, Tak Y Leung, Rossa WK Chiu, Hannah Valantine, KC Allen Chan, YM Dennis Lo   +18 more
doaj   +1 more source

Identification of germline cancer predisposition variants during clinical ctDNA testing

, 2021
Next-generation sequencing of circulating tumor DNA (ctDNA) is a non-invasive method to guide therapy selection for cancer patients. ctDNA variant allele frequency (VAF) is commonly reported and may aid in discerning whether a variant is germline or ...
Bryan P. Schneider, Schneider, Bryan P., Philips, Santosh, Leigh Anne Stout, Santosh Philips, Hunter, Cynthia, Nawal Kassem, Stout, Leigh Anne, Radovich, Milan, Milan Radovich, Cynthia Hunter, Kassem, Nawal   +11 more
core   +1 more source

Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care

Journal of Laboratory Medicine, 2022
The liquid profiling approach is currently at the threshold of translation from research application in various clinical trials to introduction into the management of cancer patients in the context of clinical care.
Froelich Matthias F., Schoenberg Stefan O., Neumaier Michael, Haselmann Verena   +3 more
doaj   +1 more source

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Cancer Biology & Medicine, 2021
Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer.
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan   +13 more
doaj   +1 more source

Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Study. [PDF]

MedComm (2020)
A total of 127 advanced pancreatic ductal adenocarcinoma (PDAC) patients receiving first‐line therapy were enrolled in this study. A series of peripheral blood collected before the initiation of treatment (B1), at the first response assessment (B2), and at subsequent timepoints to perform high‐depth next‐generation sequencing.
You T, Tang H, Yuan M, Song D, Wang C, Ying J, Chen R, Bai C, Cheng Y, Wang Y.   +9 more
europepmc   +2 more sources

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Cancers, 2022
Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts.
Josep Gumà, Karla Peña, Francesc Riu, Carmen Guilarte, Anna Hernandez, Clara Lucía, Francisca Martínez-Madueño, Maria José Miranda, Inés Cabezas, Marc Grifoll, Sergio Peralta, Sara Serrano, Félix Muñoz, Lola Delamo, Barbara Roig, Joan Borràs, Joan Badia, Marta Rodriguez-Balada, David Parada   +18 more
openaire   +2 more sources

Current and Future Clinical Applications of ctDNA in Immuno-Oncology

, 2021
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive opportunity to diagnose, characterize, and monitor the disease in individual cancer patients.
Pantel, Klaus, Heidrich, Isabel, Keller, Laura, Gebhardt, Christoffer, Sementsov, Mark, Belloum, Yassine, Stadler, Julia-Christina, Deitert, Benjamin   +7 more
core   +1 more source

Mitochondria‐Damaging Self‐Reporting Probe for Cancer Therapy

Angewandte Chemie, EarlyView.
We developed a class of self‐reporting cationic chemotherapeutic probes that selectively induce mitochondrial damage and apoptosis in cancer cells. Their unique mitochondria‐to‐nucleus fluorescence migration enables real‐time visualization of the therapeutic process. ABSTRACT Mitochondrial damage induced by chemotherapeutic agents through disruption of
Hai Xu, Yura Lee, Sanghee Yoon, Yun Wang, Yejin Cho, Seongyu Choi, Lu Lu, Hua Zhang, Sun Choi, Ki Taek Nam, Juyoung Yoon   +10 more
wiley   +2 more sources